CagriSema vs Orforglipron
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CagriSema
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide, developed by Novo Nordisk. By combining two distinct appetite-regulating peptide hormones, CagriSema aims to achieve greater weight loss than semaglutide alone. Phase 3 data showed 22.7% body weight reduction, and an FDA response is expected in 2026.
Full details →Orforglipron
Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (which is a peptide requiring special formulation), orforglipron is a small molecule — the first of a new class of oral GLP-1 drugs that can be taken without fasting restrictions. It is in Phase 3 trials for obesity and type 2 diabetes, with an FDA decision expected in 2026. Projected to reach $16 billion in annual sales by 2031.
Full details →Side-by-Side Comparison
| Aspect | CagriSema | Orforglipron |
|---|---|---|
| Mechanism | CagriSema combines two complementary peptide mechanisms: (1) Semaglutide — GLP-1 receptor agonist providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite suppression. (2) Cagrilintide — a long-acting analog of amylin, a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus, providing additional appetite suppression via a distinct neuronal pathway from GLP-1. The combination produces additive weight loss by engaging two independent satiety signaling systems. | Orforglipron is a small-molecule agonist that binds and activates the GLP-1 receptor through the same signaling cascade as peptide GLP-1 agonists (cAMP elevation, insulin secretion, appetite suppression) but with a fundamentally different molecular structure. Being a non-peptide, it does not require protection from enzymatic degradation (no fatty acid conjugation needed), can be absorbed without special formulation, and has no fasting restrictions for administration. Once-daily oral dosing with a half-life of ~25-65 hours. |
| Typical Dosage | Phase 3 trial doses: cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (fixed combination in a single injection). Dose escalation: start at cagrilintide 0.15 mg / semaglutide 0.25 mg weekly and escalate over 16 weeks to the maintenance dose. Administered as a single injection combining both peptides. | Phase 2 trial doses: 12 mg, 24 mg, 36 mg, and 45 mg daily. The 36 mg and 45 mg doses showed greatest efficacy. Phase 3 trials are evaluating doses of 12-60 mg daily. No fasting requirement — can be taken with or without food at any time of day. Final approved dosing not yet established. |
| Administration | Single subcutaneous injection once weekly, combining both peptides. Pre-filled pen device. Not yet commercially available. FDA response expected 2026. | Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available. |
| Side Effects | Phase 3 data: nausea, vomiting, diarrhea, constipation (similar profile to semaglutide alone, but some reports suggest modestly higher GI rates). Decreased appetite. Injection site reactions. | Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%. |
| Best For |
What They Have in Common
CagriSema, Orforglipron are both commonly used for:
Detailed Analysis
Commonalities
Both CagriSema and Orforglipron are commonly used for Weight Loss, Diabetes Management.
Which Should You Choose?
CagriSema has stronger evidence for Weight Loss.
Ready to Learn More?
Looking for trusted sources?